×
Aldeyra Therapeutics Long Term Debt 2014-2025 | ALDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Aldeyra Therapeutics long term debt from 2014 to 2025. Long term debt can be defined as the sum of all long term debt fields.
View More
Aldeyra Therapeutics Long Term Debt 2014-2025 | ALDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Aldeyra Therapeutics long term debt from 2014 to 2025. Long term debt can be defined as the sum of all long term debt fields.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$81.3B
Zoetis (ZTS)
$67.2B
Daiichi Sankyo, - (DSNKY)
$46.3B
Takeda Pharmaceutical (TAK)
$45.6B
BeOne Medicines - (ONC)
$33.5B
Sandoz Group AG (SDZNY)
$26B
Summit Therapeutics (SMMT)
$19.9B
Merck (MKKGY)
$16.9B
Shionogi (SGIOY)
$14.3B
United Therapeutics (UTHR)
$13.4B
Neurocrine Biosciences (NBIX)
$13.3B
Orion OYJ (ORINY)
$11.4B
IPSEN (IPSEY)
$10.8B
Stevanato Group S.p.A (STVN)
$7.7B
Corcept Therapeutics (CORT)
$7.2B
Grifols, S.A (GRFS)
$7.2B
Ionis Pharmaceuticals (IONS)
$6.6B
Madrigal Pharmaceuticals (MDGL)
$6.5B
Hikma Pharmaceuticals Plc (HKMPF)
$6.2B
Ono Pharmaceutical (OPHLF)
$5.2B
Soleno Therapeutics (SLNO)
$4.2B
Hypermarcas (HYPMY)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.7B
Catalyst Pharmaceuticals (CPRX)
$2.6B
NewAmsterdam Pharma (NAMS)
$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2B
Ocular Therapeutix (OCUL)
$1.9B
Endo (NDOI)
$1.8B
ARS Pharmaceuticals (SPRY)
$1.7B